Antitumor activity of sphingosine kinase inhibitors

Area of Science:

• Oncology
• Biochemistry
• Pharmacology

Background:

• Sphingosine kinase (SK) is an oncogenic enzyme synthesizing sphingosine-1-phosphate (S1P), a mitogenic mediator, from proapoptotic ceramide.
• Targeting SK offers a therapeutic strategy for cancer by inhibiting proliferation and inducing apoptosis.

Purpose of the Study:

• To evaluate the in vitro and in vivo efficacy of novel SK inhibitors.
• To assess the pharmacokinetic properties and antitumor activity of these compounds in preclinical models.

Main Methods:

• In vitro enzyme inhibition assays and cell signaling analyses.
• In vivo antitumor efficacy studies in mice, including pharmacokinetic assessments.
• Oral bioavailability and blood concentration analysis of SK inhibitors.

Main Results:

• Three structurally diverse SK inhibitors exhibited antitumor activity in mice without toxicity.
• SK inhibitors achieved blood and tumor concentrations exceeding in vitro potency.
• SKI-II demonstrated oral bioavailability, sustained blood presence, and significant tumor growth inhibition.

Conclusions:

• Novel non-lipid selective SK inhibitors possess in vivo antitumor activity.
• These findings provide promising leads for developing new cancer therapeutics targeting SK.
• Further development of these SK inhibitors is warranted for clinical applications.